NOVOLOG MIX 70/30 PENFILL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 PENFILL (NOVOLOG MIX 70/30 PENFILL).
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
| Metabolism | Insulin aspart is primarily metabolized by proteolytic degradation, likely by insulin-degrading enzyme (IDE) and other proteases; no significant cytochrome P450 involvement. |
| Excretion | Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible. |
| Half-life | Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing. |
| Protein binding | <10% bound to plasma proteins (insulin aspart; no significant binding). Protamine may bind non-specifically. |
| Volume of Distribution | 0.1-0.3 L/kg (insulin aspart; reflects distribution into extracellular fluid). Clinical meaning: small Vd indicates limited tissue binding. |
| Bioavailability | Subcutaneous: 60-80% (insulin aspart; variability due to injection site, local blood flow, and lipodystrophy). |
| Onset of Action | Subcutaneous: 10-20 minutes (rapid-acting insulin aspart component). |
| Duration of Action | Subcutaneous: up to 24 hours (due to protamine-crystallized insulin aspart component; prolonged, flat basal effect). Clinical notes: peakless basal coverage; administer within 15 minutes before or after meals. |
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30–60 mL/min: monitor glucose and reduce dose as needed; eGFR <30 mL/min: dose reduction recommended due to increased hypoglycemia risk. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B or C: dose reduction may be required due to impaired gluconeogenesis; monitor glucose. |
| Pediatric use | Individualized based on weight: starting dose 0.5–1 unit/kg/day divided into two doses; adjust according to blood glucose targets. |
| Geriatric use | Start with lower doses (e.g., 0.3–0.5 unit/kg/day) and titrate carefully to avoid hypoglycemia; consider comorbid conditions and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 PENFILL (NOVOLOG MIX 70/30 PENFILL).
| Breastfeeding | Insulin aspart is excreted into breast milk in negligible amounts. The M/P ratio is not established but likely very low. Oral bioavailability to the infant is minimal due to degradation in the GI tract. The drug is considered compatible with breastfeeding. Monitor infant for signs of hypoglycemia if high doses are used. |
| Teratogenic Risk | Insulin aspart protamine and insulin aspart (Novolog Mix 70/30) do not cross the placenta in significant amounts. No teratogenic effects have been reported in human studies. Uncontrolled maternal diabetes increases risks of congenital anomalies, macrosomia, and neonatal hypoglycemia. During the first trimester, strict glycemic control is essential. In second and third trimesters, the risk of fetal harm is primarily from maternal hyperglycemia, not the drug itself. |
■ FDA Black Box Warning
None
| Common Effects | Application site reactions burning irritation itching and redness |
| Serious Effects |
["Hypersensitivity to insulin aspart or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: May be severe and life-threatening; risk increased with intensive glucose control, missed meals, exercise, or hepatic/renal impairment.","Switching between insulin products: Requires close monitoring due to differences in pharmacokinetics.","Hyperglycemia or ketoacidosis: Risk if insulin is discontinued or dosing errors occur.","Hypokalemia: Insulin can cause potassium shifts; caution in patients at risk.","Fluid retention and heart failure: Concomitant use of thiazolidinediones may cause fluid retention.","Injection site reactions: Lipoatrophy or lipohypertrophy can occur; rotate injection sites."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently (at least 4-6 times daily), HbA1c every 1-2 months, and ketones if hyperglycemia occurs. Fetal monitoring includes ultrasound for growth and amniotic fluid index, nonstress tests, and biophysical profiles in third trimester. Watch for macrosomia and polyhydramnios. |
| Fertility Effects | No direct adverse effects on fertility reported. Uncontrolled diabetes can impair fertility due to hormonal imbalances. Improved glycemic control with insulin may restore normal fertility. |